Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid‐Treated Oncology Patients
Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid‐Treated Oncology Patients
About this item
Full title
Author / Creator
Publisher
Hoboken, USA: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken, USA: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
Several opioids have pharmacogenomic associations impacting analgesic efficacy. However, germline pharmacogenomic testing is not routinely incorporated into supportive oncology. We hypothesized that CYP2D6 profiling would correlate with opioid prescribing and hospitalizations.
Materials and Methods
We analyzed 61,572 adult oncol...
Alternative Titles
Full title
Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid‐Treated Oncology Patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8571740
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8571740
Other Identifiers
ISSN
1083-7159
E-ISSN
1549-490X
DOI
10.1002/onco.13953
